Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00705757 · ClinicalTrials.gov registry record · Phase 4
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
A Phase 4 study, sponsored by Summa Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT00705757: Completed Phase 4 study, sponsored by Summa Health System.
NCT00705757 is a Phase 4 study that has completed, run by Summa Health System. The registered enrollment target is 89 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00705757, a Phase 4 study, has completed, sponsored by Summa Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan.
Primary Outcome
Periocular skin color was measured with the Minolta Chroma Meter CR-400 and the L\*a\*b\* system, also known as Commission Internationale de l'Eclairage. This is a well-accepted unit of measurement in which L\* corresponds to brightness and a\* and b\* correspond to chromaticity. Measurements were taken at baseline and 1 year. Data from each time point and each location (upper and lower eyelids or cheeks/face) were averaged, and subtracted from the baseline value for that location. Six predeter
Interventions
- DRUG latanoprost
- DRUG bimatoprost
- DRUG travoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-03 |
| Est. Completion | 2011-04 |
| Phase | Phase 4 |
What the finished NCT00705757 record still lists
NCT00705757 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which latanoprost is the first listed.
NCT00705757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00705757 about?
NCT00705757 is a clinical study titled "The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye". The purpose of this study is to study changes in skin color that may be caused by using one of the three eye medicines: Xalatan, Travatan or Lumigan.
What is the current status of trial NCT00705757?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2008-03. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00705757?
The interventions under investigation include: latanoprost (DRUG), bimatoprost (DRUG), travoprost (DRUG).
Who is sponsoring clinical trial NCT00705757?
This trial is sponsored by Summa Health System, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00705757's enrollment target sits among peer trials
89 913th of 2000 higher than 1,085 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia